Working… Menu
Trial record 58 of 1593 for:    veterans affairs medical center

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00448942
Recruitment Status : Completed
First Posted : March 19, 2007
Last Update Posted : March 19, 2007
Weill Medical College of Cornell University
Washington University School of Medicine
Johns Hopkins University
University of Tennessee
Centers for Disease Control and Prevention
Information provided by:
Hunter Holmes Mcguire Veteran Affairs Medical Center

Brief Summary:
The purpose of this study was to determine if the use of daily chlorhexidine bathing would decrease the incidence of MRSA and VRE colonization and healthcare associated Bloodstream Infections (BSI) among Intensive Care Unit (ICU) patients.

Condition or disease Intervention/treatment
Nosocomial Bacteremia Nosocomial Fungemia MRSA Colonization MRSA Infection VRE Colonization VRE Infection Behavioral: Daily bathing with Chlorhexidine based product

Detailed Description:

Infections due to Staphylococci including MRSA are the predominant nosocomially acquired complication in the intensive care unit. The increasing incidence of MRSA colonization and infection among ICU patients has been attributed to many factors including increased admission of patients already colonized with MRSA to the ICU, poor compliance with handwashing and barrier precautions, delayed identification of MRSA colonized patients, and understaffing. Measures that have proven to limit horizontal transmission between patients and staff and staff to patients include strict attention to barrier precautions and handwashing. Unfortunately both of these strategies require levels of compliance that are often not achieved.

Nosocomial blood stream infections are a leading source of morbidity and mortality among intensive care unit patients. Several modifiable factors have been shown to increase the risk of bloodstream infections. These include lapses in the use of strict sterile technique in the insertion of central venous catheters and improper site preparation. New CDC guidelines on the prevention of catheter related bloodstream infections recommend that the preferential use of chlorhexidine containing skin disinfectants be used for site preparation prior to insertion. The use of chlorhexidine reduces residual skin organisms as well as inhibits their rebound growth and has been demonstrated to reduce catheter-associated bloodstream infections in comparison to other skin disinfectant products such as povidone-iodine.

As a result of guidelines promoting the use of chlorhexidine, a number of intensive care units have implemented quality improvement projects examining the potential role of chlorhexidine based bathing of intensive care unit patients in reducing nosocomial transmission of multiresisitant organisms such as MRSA and vancomycin-resistant enterocooci (VRE). The goal of the currently proposed study is to analyse existing data from participating intensive care units that have adopted the use of chlorhexidine antisepsis to determine the impact of chlorhexidine on bacterial colonization and nosocomial infections Participating hospitals who have completed quality improvement projects that included the use of chlorhexidine in bathing of ICU patients will submit de-identified data on nosocomial bacteremias and MRSA and VRE colonization during defined time periods where chlorhexidine bathing was used in comparison to time periods where regular bathing procedures were utilized.

Layout table for study information
Study Type : Observational
Enrollment : 5300 participants
Observational Model: Defined Population
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Retrospective
Official Title: The Impact of the Use of Chlorhexidine-Based Bathing System in the Hospital to Reduce the Incidence of MRSA/VRE Infection or Colonization and Nosocomial Bloodstream Infections (BSI)
Study Start Date : November 2004
Actual Study Completion Date : January 2006

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All adult patients admitted to study units

Exclusion Criteria:

  • Children under the age of 18
  • Previous adverse reaction or documented allergy to chlorhexidine based products

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00448942

Layout table for location information
United States, Maryland
Johns Hopkins Hospital
Baltimore, Maryland, United States, 21205
United States, Missouri
Barnes Jewish Hospital
St. Louis, Missouri, United States, 63110
United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10021
United States, Virginia
Hunter Holmes McGuire Veteran Affairs Medical Center
Richmond, Virginia, United States, 23249
Sponsors and Collaborators
Hunter Holmes Mcguire Veteran Affairs Medical Center
Weill Medical College of Cornell University
Washington University School of Medicine
Johns Hopkins University
University of Tennessee
Centers for Disease Control and Prevention
Layout table for investigator information
Principal Investigator: Edward W Wong, MD Hunter Holmes Mcguire Veteran Affairs Medical Center

Layout table for additonal information Identifier: NCT00448942     History of Changes
Other Study ID Numbers: 01115
First Posted: March 19, 2007    Key Record Dates
Last Update Posted: March 19, 2007
Last Verified: March 2007
Keywords provided by Hunter Holmes Mcguire Veteran Affairs Medical Center:
Staphylococcus aureus [B03.510.400.790.750.100]
Enterococcus faecalis [B03.510.400.800.280.280]
Enterococcus faecium [B03.510.400.800.280.300]
Bacteremia [C01.252.100]
Fungemia [C01.703.360]
Infection Control [G03.850.780.200.450]
Antisepsis [G03.850.780.200.450.150]
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Bacterial Infections
Systemic Inflammatory Response Syndrome
Pathologic Processes
Invasive Fungal Infections
Chlorhexidine gluconate
Anti-Infective Agents, Local
Anti-Infective Agents
Dermatologic Agents